---
title: "Haleos Labs Limited (HALEOSLABS) — Share Price, Financials & Analysis"
symbol: "HALEOSLABS"
company: "Haleos Labs Limited"
canonical: "https://tapetide.com/stocks/HALEOSLABS"
isin: "INE320X01016"
nse_symbol: "HALEOSLABS"
bse_code: "540679"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 437.47
generated_at: "2026-09-13T18:46:37.459Z"
---

# Haleos Labs Limited (HALEOSLABS)

Canonical page: https://tapetide.com/stocks/HALEOSLABS

## Company

- **NSE Symbol:** HALEOSLABS
- **BSE Code:** 540679
- **ISIN:** INE320X01016
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2017-08-17
- **CEO:** Mr. Talluri Veera Venkata Satyanarayana Murthy
- **Employees:** 592
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** haleoslabs.com

## About

Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]

## Latest Price

- **Price:** ₹1462.5
- **Change:** +11.9 (+0.82%)
- **Open:** ₹1450.6
- **Day High:** ₹1500
- **Day Low:** ₹1437
- **Previous Close:** ₹1450.6
- **Volume:** 382
- **As Of:** 2026-09-11T09:59:57+00:00

## Key Fundamentals

Observed at 2026-09-11T04:39:53.887983Z.

- **Market Cap:** ₹437.47 Cr
- **Classification:** Microcap
- **P/E (reported):** 28.7
- **P/E (TTM):** 27.96
- **EPS (TTM):** ₹52.31
- **Book Value:** ₹706.33
- **Price to Book:** 2.05
- **Dividend Yield:** 0.1%
- **ROE:** 8.83%
- **ROCE:** 14.08%
- **Debt to Equity:** 0.52
- **Revenue (yearly):** ₹333.79 Cr
- **Net Income:** ₹19.88 Cr
- **EBITDA:** ₹44.67 Cr
- **52-Week High:** ₹1774
- **52-Week Low:** ₹1091.1
- **RSI (14):** 44.12

## Tapetide Score

- **Score:** 49 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Rising
- **Percentile:** 43.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 32.18 | 9% |
| growth | 32.87 | 9% |
| momentum | 71.42 | 12% |
| ownership | 50.19 | 24% |
| quality | 53.14 | 22% |
| valuation | 42.94 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- The company has delivered a poor sales growth of 4.68% over past five years.
- Company has a low return on equity of 8.24% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 40.11% | 131.7% | -3.16% |
| ebitda margin growth | 54.84% | -6.87% | 17.82% | 29.15% |
| net income growth | 500% | 6.31% | 20% | 5% |
| revenue growth | -4.8% | -4.52% | 2% | 5% |
| roce | 129.18% | 73.19% | 57.32% | 12.31% |
| roe | 441.18% | 170.03% | 6.05% | -15.82% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.6 | 89.11 | 82.5 | 81.37 | 94.78 | 75.14 | 72.94 |
| Expenses | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 | 70.98 | 63.82 |
| Operating Profit | 7.93 | 9.3 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 | 4.16 | 9.12 |
| OPM % | 11.45 | 12.91 | 12.62 | 17.59 | 10.92 | 15.07 | 8.33 | 14.19 | 16.69 | 14.82 | 5.54 | 12.5 |
| Other Income | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1 | 0.42 | 0.18 | 2.01 | 0.46 |
| Interest | 2.81 | 2.34 | 2.84 | 2.4 | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 | 1.42 | 1.9 |
| Depreciation | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.8 | 3.82 | 3.89 | 3.91 | 3.85 | 4.24 |
| Profit before tax | 1.66 | 3.81 | 7.1 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 | 0.9 | 3.44 |
| Tax % | 126.51 | -8.14 | 8.73 | 33.27 | 29.72 | 29.81 | 11.45 | 37.61 | 24.38 | 24.26 | 62.22 | 46.51 |
| Net Profit | -0.44 | 4.12 | 6.47 | 7.1 | 3.3 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 | 0.35 | 1.84 |
| EPS in Rs | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.9 | 1.46 | 8.77 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 334 | 324 |
| Expenses | 343 | 235 | 235 | 316 | 287 | 275 | 300 | 289 | 283 |
| Operating Profit | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 45 | 41 |
| OPM % | 9 | 10 | 11 | 10 | 9 | 10 | 13 | 13 | 13 |
| Other Income | 2 | 2 | 2 | 14 | 5 | 4 | 5 | 2 | 3 |
| Interest | 6 | 5 | 5 | 6 | 7 | 10 | 9 | 6 | 6 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 15 | 15 | 15 | 16 |
| Profit before tax | 25 | 15 | 20 | 33 | 17 | 10 | 26 | 25 | 22 |
| Tax % | 30 | 31 | 31 | 23 | 31 | 36 | 28 | 29 | — |
| Net Profit | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 18 | 15 |
| EPS in Rs | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 66.52 | 57.26 | 52.31 |
| Dividend Payout % | 3 | 0 | 3 | 2 | 4 | 5 | 2 | 3 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 211 |
| Borrowings | 47 | 65 | 65 | 80 | 100 | 101 | 86 | 111 |
| Other Liabilities | 116 | 72 | 108 | 125 | 126 | 114 | 107 | 130 |
| Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Fixed Assets | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 268 |
| CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 0 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 176 |
| Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 30 | 15 | 35 | -11 | 15 | 24 | 34 | 37 |
| Cash from Investing Activity | -44 | -27 | -26 | -7 | -31 | -18 | -15 | -58 |
| Cash from Financing Activity | 15 | 12 | -3 | 11 | 17 | -7 | -19 | 21 |
| Net Cash Flow | 1 | 0 | 6 | -8 | 0 | -1 | 0 | 1 |
| Free Cash Flow | 6 | -9 | 0 | -53 | -28 | 4 | 19 | -21 |
| CFO/OP | 105 | 69 | 133 | -10 | 62 | 88 | 94 | 98 |

### Ratios

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 40 | 30 | 47 | 35 | 53 | 61 | 73 | 67 |
| Inventory Days | 116 | 149 | 164 | 159 | 184 | 196 | 160 | 210 |
| Days Payable | 140 | 101 | 163 | 146 | 127 | 143 | 126 | 162 |
| Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 | 115 | 106 | 116 |
| Working Capital Days | 14 | 18 | 2 | 17 | 24 | 11 | 7 | 5 |
| ROCE % | — | 12 | 13 | 12 | 8 | 7 | 12 | 10 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 70.32% | 70.68% | 71.19% | 71.41% | 71.41% | 71.41% | 71.41% | 71.41% | 71.41% | 71.8% | 72.11% | 72.11% |
| FIIs | 0% | 0% | 0% | 0.01% | 0.02% | 0% | 0% | 0.03% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.03% | 0.29% | 0.3% | 0.31% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 26.01% | 25.69% | 25.64% | 25.56% | 25.56% | 25.51% | 25.55% | 25.55% | 25.32% | 24.61% | 24.33% | 23.99% |
| Others | 3.67% | 3.63% | 3.17% | 3.02% | 3.01% | 3.08% | 3.04% | 3.01% | 3.25% | 3.31% | 3.27% | 3.59% |
| No. of Shareholders | 8443 | 8233 | 8116 | 7861 | 7849 | 7626 | 7479 | 7412 | 7521 | 7125 | 6937 | 6859 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 5 / 4 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1465.37 | Sell |
| EMA (10) | 1465.68 | Sell |
| SMA (20) | 1474.24 | Sell |
| EMA (20) | 1473.83 | Sell |
| SMA (50) | 1515.05 | Sell |
| EMA (50) | 1485.53 | Sell |
| SMA (100) | 1501.64 | Sell |
| EMA (100) | 1465.32 | Sell |
| SMA (200) | 1394.59 | Buy |
| EMA (200) | 1408.49 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 46.7 | Neutral |
| MACD (12,26,9) | -10.8 | Sell |
| Stochastic (14,3,3) | 16.79 | Buy |
| ADX (14) | 10.52 | Neutral |
| Williams %R (14) | -80.61 | Buy |
| ATR (14) | 59.13 | High Volatility |
| ROC (12) | -2.56 | Sell |
| Stoch RSI (14) | 45.86 | Neutral |
| UO (7,14,28) | 24.41 | Buy |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Annual Report (Weblink)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c1d4b89-81ea-46f5-8478-54b44297eb59.pdf) |
| 2026-09-08 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df3fc54e-8fa3-495d-b061-9f9838ea6513.pdf) |
| 2026-09-08 | [AGM Notice (Sept 30 2026)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12458cb6-4c80-45c6-9163-c35108fa3060.pdf) |
| 2026-09-08 | [Newspaper Advertisement (AGM Notice)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=afeb58a1-6e92-4286-af4e-afe311b63fc4.pdf) |
| 2026-09-05 | [Events Calendar (AGM)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a0d1ee2-f772-4d8c-a21b-a34f76df669e.pdf) |
| 2026-09-05 | [Record Date (Dividend)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6a9a7d4-c781-4d9d-a30a-152c09e7ba12.pdf) |
| 2026-09-01 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ecc8154e-4384-4b7a-9060-1586aa697e45.pdf) |
| 2026-09-01 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1984750-3249-4698-8e8c-166ab4217116.pdf) |
| 2026-08-24 | [Communication To Shareholders (TDS Related)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5077b357-2f94-412b-84a4-e2d52265729b.pdf) |
| 2026-08-07 | [Newspaper Publication (Financial Results)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=53030474-acd0-4201-83f7-5f2c20950492.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-30 | [Financial Results (Q4/F26)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92bf1ebc-968c-4e50-9bef-b29afaa0a289.pdf) |
| 2025-08-11 | [Financial Results (Q1/F26)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5f3bff1a-1e7d-49ba-a77e-d62c144bc736.pdf) |
| 2025-05-29 | [Financial Results (Q4/F25)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2032259d-a352-49ef-bc31-fc6ef9bf2497.pdf) |
| 2025-02-12 | [Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab704982-5761-4bda-8c95-4e071b67ffcd.pdf) |
| 2024-05-27 | [Audited (Standalone & Consolidated) Financial Results For The Quarter And Year Ended 31St March, 2024, As Recommended By Audit Committee.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=836cd85b-3327-4cd2-8b51-79434d13c226.pdf) |
| 2023-05-29 | [Board Meeting Outcome for Outcome Of 85Th Board Meeting (29.05.2023)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77e41199-6c80-4872-8f44-09f1b2569dff.pdf) |
| 2023-02-10 | [Board Meeting Outcome for Financial Results For Quarter And Nine Months Ended December 31, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14df2265-1026-4b83-8c65-0fb5e85f30c6.pdf) |
| 2022-11-22 | [Related Party Transactions (H1 F23)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27f68acc-c97c-4d8c-bc06-28247e55d9b6.pdf) |
| 2022-11-14 | [Board Meeting Outcome for Financial Results For Quarter And Half Year Ended September 30, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=408230ba-d6a8-42a3-9043-dbf9c7e5e5d9.pdf) |
| 2022-08-09 | [Board Meeting Outcome for Financial Results For Quarter Ended June 30, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bbd529c0-5e4e-437b-aaef-ced76a8a0c5a.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 Apr - Suresh Babu Potluri confirms continued compliance for approved reclassification under SEBI Regulation 31A. | [Annual Confirmation (Reclassification) 8 Apr - Suresh Babu Potluri confirms continued compliance for approved reclassification under SEBI Regulation 31A.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/80322d12-4cd0-42be-8eff-b0851c443745.pdf) |
| 8 Apr - Promoters disclosed no share encumbrance for FY2025-26. | [Encumbrance (Annual Disclosure) 8 Apr - Promoters disclosed no share encumbrance for FY2025-26.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/636a64ed-a75c-442c-96bb-7ac6d34e89ab.pdf) |
| 4 Feb - Board to meet Feb 11, 2026 to consider unaudited Q3/9M results; trading window closed till Feb 15. | [Board Meeting Intimation for 96Th Board Meeting (11.02.2026) 4 Feb - Board to meet Feb 11, 2026 to consider unaudited Q3/9M results; trading window closed till Feb 15.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/769eba91-903d-4d10-9197-ac239e56a5dc.pdf) |
| 30 Mar - Updated email IDs and website due to name change; shareholders informed March 30, 2026. | [New Email ID & Website 30 Mar - Updated email IDs and website due to name change; shareholders informed March 30, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3eb44059-f768-44d8-b266-9d8083eddfb8.pdf) |
| 30 Mar - Postal ballot to approve ₹20 Crore (USD2.2M) corporate guarantee for Mahi Drugs' ECB; voting Mar31–Apr29. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 30 Mar - Postal ballot to approve ₹20 Crore (USD2.2M) corporate guarantee for Mahi Drugs' ECB; voting Mar31–Apr29.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/86070b69-50c5-4730-ab27-bc698ca149e6.pdf) |
| 28 Feb - Haleos Labs reopens Feb 5, 2026–Feb 4, 2027 window to re-lodge pre-April 1, 2019 physical share transfers. | [Special Window (Physical Shares) 28 Feb - Haleos Labs reopens Feb 5, 2026–Feb 4, 2027 window to re-lodge pre-April 1, 2019 physical share transfers.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/053ece45-7b90-4d21-a064-9bd9551e9bb3.pdf) |
| 26 Mar - Postal ballot to approve corporate guarantee to RBL Bank for subsidiary's borrowing; e-vote Mar31–Apr29; result May1,2026. | [Events Calendar (Postal Ballot) 26 Mar - Postal ballot to approve corporate guarantee to RBL Bank for subsidiary's borrowing; e-vote Mar31–Apr29; result May1,2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3603644d-23a6-4f8e-902d-db2f4899d9c1.pdf) |
| 20 Mar - Trading window closed from Apr 1, 2026 until 48 hours after results for quarter/year ended Mar 31, 2026. | [Closure of Trading Window 20 Mar - Trading window closed from Apr 1, 2026 until 48 hours after results for quarter/year ended Mar 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bc77d736-ab58-45dc-9a55-47f269fbc8e9.pdf) |
| 11 Feb - Board approved Q3/nine-month Dec 31, 2025 results; proposes Rs20 crore guarantee for subsidiary, postal ballot planned. | [Board Meeting Outcome for Meeting Held On February 11, 2026 11 Feb - Board approved Q3/nine-month Dec 31, 2025 results; proposes Rs20 crore guarantee for subsidiary, postal ballot planned.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4c703b0e-c587-4750-bdd4-8c4f8d34786b.pdf) |
| 1 May - Postal ballot passed approving corporate guarantee for Mahi Drugs' ECB facility with RBL Bank, effective April 29, 2026. | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 1 May - Postal ballot passed approving corporate guarantee for Mahi Drugs' ECB facility with RBL Bank, effective April 29, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e77fc585-0802-4dc4-967d-c0e8bf2cc7ad.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2025-07-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93c18c6b-9e5e-4fc3-80d3-1a7accc00f8d.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/93c18c6b-9e5e-4fc3-80d3-1a7accc00f8d.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a2bd0c92-43eb-475a-923f-e0e1a15079b9.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/04f1931a-2864-446f-93b6-b49dae2941e9.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cf5dc856-5e1e-4dcf-8133-da48803c7d8e.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540679/76868540679.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/540679/72319540679.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/540679/67000540679.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/540679/5406790319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/540679/5406790318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/HIS_ANN_RPT/HISTANNR/2017/SMS_LIFESCIENCES_INDIA_LTD-540679-MARCH-2017.PDF) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:46:37.459Z.